Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October in Boston, MA.
With 20+ world-class speakers and over 100 senior attendees from around the globe, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy!
Here’s your exclusive snapshot of the world class speaker faculty:
- Michael Lotze, Chief Cellular Therapy Officer, Nurix Therapeutics
- Mark Dudley, Chief Scientific Officer, InsTIL Bio
- Daniel J Powell Jr, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
- Parameswaran Hari, SVP Clinical Sciences, Iovance Biotherapeutics
- Nick Restifo, Stealth Explorer, Immunotherapy
- Karrie Wong, Director Cell Therapy, KSQ Therapeutics
- Andrew Weinberg, Chief Scientific Officer, AgonOx
- Jan Ter Meulen, Chief Scientific Officer, Obsidian Therapeutics
- Tom Henley, Chief Scientific Officer, Intima Biosciences
- Stephanie Woodall, Director – Head of Quality, KSQ Therapeutics
- Sylvia Lee, Associate Professor, Program in Immunology Clinical Research Division, Fred Hutchinson Cancer Research Center
- Ulrik Cordes, Founder & Chief Executive Officer, Cbio
Learn from pioneering trailblazers in TIL development from the National Cancer Institute & University of Pennsylvania alongside leading industry representatives from the likes of Iovance, Instil Bio and Obsidian Therapeutics.
As a host of developers look to bridge to the next generation of TIL therapies, now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development.
Join senior leaders from leading biotech, clinical and academic institutes to discuss data-driven and solution-based approaches to supercharge your TIL therapy towards commercialization.
To know more visit: https://ter.li/ygtovu